Webinar | Getting the best data from your cells: From tissue culture to final analysis
Sign Up to like & getrecommendations! Published in 2017 at "Science"
DOI: 10.1126/science.356.6336.446-b
Abstract: From tissue culture to final analysis, cell culture is a group of techniques used in the majority of life science laboratories. There are numerous standard methodologies, but many of the techniques used are continuously changing… read more here.
Keywords: webinar getting; tissue culture; final analysis; culture final ... See more keywords
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-1092
Abstract: Abstract Purpose: In PERTAIN's primary analysis (31 months’ median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untreated HER2-positive and hormone receptor–positive… read more here.
Keywords: pertuzumab trastuzumab; final analysis; pertuzumab; analysis ... See more keywords
Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct216
Abstract: Background: The Ph III IMpower150 study (NCT02366143) showed PFS and OS benefit with atezo + bev + carboplatin (carbo) + paclitaxel (pac; ABCP; Arm B) vs bev + carbo + pac (BCP; Arm C) as… read more here.
Keywords: key subgroups; analysis; final analysis; bev ... See more keywords
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-07-795047
Abstract: This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18),… read more here.
Keywords: survival outcomes; treatment; trial; final analysis ... See more keywords
Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2023010026
Abstract: CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) versus carfilzomib and dexamethasone (Kd) in adults with relapsed/refectory multiple myeloma (RRMM) with 1-3 prior therapies. The CANDOR study met… read more here.
Keywords: carfilzomib; carfilzomib dexamethasone; final analysis; candor ... See more keywords
Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.141
Abstract: 141 Background: The first and second interim analyses (IA1 and IA2) of the LATITUDE study in NDx-HR mCNPC pts with addition of AA+P to ADT vs placebo (PBO)+ADT showed significant benefit in the coprimary endpoints… read more here.
Keywords: ndx mcnpc; analysis; final analysis; latitude study ... See more keywords
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5062
Abstract: 5062Background: Tivozanib (T) is a potent and highly selective VEGFR inhibitor. TIVO-3 is a phase 3 study designed to compare the efficacy and safety of T with those of sorafenib (S) as 3rd and 4th... read more here.
Keywords: analysis phase; phase; final analysis; study ... See more keywords